The page lists 29 projects related to the topic "nash".
# | |||
---|---|---|---|
1 | EPoS | Elucidating Pathways of Steatohepatitis | 2015 |
2 | HEP-CAR | Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. | 2016 |
3 | DeMILI | NON INVASIVE DIAGNOSTIC TEST SERVICE FOR “NON ALCOHOLIC FATTY LIVER DISEASE” MANAGEMENT | 2016 |
4 | MAST4HEALTH | Mastiha treatment for healthy obese with NAFLD diagnosis (MAST4HEALTH). | 2016 |
5 | HepatoMetaboPath | Cellular and molecular mechanisms of metabolic immune activation triggering non-alcoholic steatohepatitis (NASH) and HCC | 2016 |
6 | RADIcAL | Non-invasive rapid assessment of chronic liver disease using Magnetic Resonance Imaging with LiverMultiScan | 2016 |
7 | Observable Stability | Evolutionary stability, observability, and efficiency | 2016 |
8 | TGDNL | Mechanisms of cellular fatty acid homeostasis | 2017 |
9 | Foie Gras | Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Fatty Liver Disease | 2017 |
10 | EXNADMINA | EXercise as a regulator of hepatic NAD metabolism and MItochondrial function in Non-Alcoholic fatty liver disease | 2016 |
11 | mtFOIE GRAS | mitoFOIE GRAS: Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease | 2017 |
12 | MAFRAN | Mathematical Frontiers in the Analysis of Many-particle Systems | 2017 |
13 | DIFFINCL | Differential Inclusions and Fluid Mechanics | 2017 |
14 | SULIPRO | A scientifically proven, safe, naturally derived drug for the effective treatment of liver damage - an innovative solution for a significant unmet medical need | 2017 |
15 | GeoMeG | Geometry of Metric groups | 2017 |
16 | NAFLDcure | A novel pharmaceutical treatment for nonalcoholic fatty liver disease | 2017 |
17 | PRELICAN | Treatment of liver disease and cancer prevention | 2017 |
18 | HEPASPHER | Mimicking liver disease and regeneration in vitro for drug development and liver transplantation | 2017 |
19 | LITMUS | Liver Investigation: Testing Marker Utility in Steatohepatitis | 2017 |
20 | N-IF | The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies | 2017 |
21 | TRANSACT | Book History and Translation History: Copyright, Wages, Censorship, and the (Proto-)Professionalisation of Translators in Nineteenth-Century Britain and Ireland | 2018 |
22 | OSTtrans | The Role of OSTα/β as a Bile Acid and Drug Transporter in Obesity-Associated Chronic Liver Disease, Nonalcoholic Fatty Liver Disease | 2018 |
23 | PhaseControl | How cellular suicide programmes control phase transitions in fatty liver disease and liver cancer | 2018 |
24 | EllipticPDE | Regularity and singularities in elliptic PDE's: beyond monotonicity formulas | 2019 |
25 | techFRONT | Novel techniques for quantitative behaviour of convection-diffusion equations | 2020 |
26 | CYPNASH | Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis | 2019 |
27 | MyeFattyLiver | Unravelling the heterogeneity and functions of hepatic myeloid cells in Non-Alcoholic Fatty Liver Disease | 2019 |
28 | EU-PEARL | EU Patient- cEntric clinicAl tRial pLatform | 2019 |
29 | MacinNASH | Revealing the contribution of liver macrophage populations to NASH in insulin resistance | 2020 |